nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—F2—atherosclerosis	0.355	1	CbGaD
Dabigatran etexilate—UGT2B15—Ezetimibe—atherosclerosis	0.21	0.479	CbGbCtD
Dabigatran etexilate—UGT2B7—Ezetimibe—atherosclerosis	0.0656	0.15	CbGbCtD
Dabigatran etexilate—UGT2B7—Simvastatin—atherosclerosis	0.061	0.139	CbGbCtD
Dabigatran etexilate—UGT2B7—Lovastatin—atherosclerosis	0.0597	0.136	CbGbCtD
Dabigatran etexilate—ABCB1—Ezetimibe—atherosclerosis	0.0113	0.0256	CbGbCtD
Dabigatran etexilate—ABCB1—Simvastatin—atherosclerosis	0.0105	0.0238	CbGbCtD
Dabigatran etexilate—ABCB1—Lovastatin—atherosclerosis	0.0102	0.0233	CbGbCtD
Dabigatran etexilate—ABCB1—Pravastatin—atherosclerosis	0.0102	0.0233	CbGbCtD
Dabigatran etexilate—F2—vein—atherosclerosis	0.00579	0.166	CbGeAlD
Dabigatran etexilate—F2—leg—atherosclerosis	0.00431	0.123	CbGeAlD
Dabigatran etexilate—F2—hindlimb—atherosclerosis	0.00385	0.11	CbGeAlD
Dabigatran etexilate—F2—appendage—atherosclerosis	0.0033	0.0943	CbGeAlD
Dabigatran etexilate—F2—artery—atherosclerosis	0.00236	0.0674	CbGeAlD
Dabigatran etexilate—F2—endothelium—atherosclerosis	0.00199	0.0569	CbGeAlD
Dabigatran etexilate—F2—blood vessel—atherosclerosis	0.00184	0.0525	CbGeAlD
Dabigatran etexilate—Transaminases increased—Lovastatin—atherosclerosis	0.00114	0.0167	CcSEcCtD
Dabigatran etexilate—Transaminases increased—Ezetimibe—atherosclerosis	0.00112	0.0164	CcSEcCtD
Dabigatran etexilate—Transaminases increased—Simvastatin—atherosclerosis	0.00107	0.0156	CcSEcCtD
Dabigatran etexilate—Transaminases increased—Pravastatin—atherosclerosis	0.000967	0.0141	CcSEcCtD
Dabigatran etexilate—F2—connective tissue—atherosclerosis	0.000942	0.0269	CbGeAlD
Dabigatran etexilate—UGT2B15—liver—atherosclerosis	0.000925	0.0264	CbGeAlD
Dabigatran etexilate—CES2—cardiovascular system—atherosclerosis	0.000914	0.0261	CbGeAlD
Dabigatran etexilate—Hepatic enzyme increased—Rosuvastatin—atherosclerosis	0.000868	0.0127	CcSEcCtD
Dabigatran etexilate—CES1—connective tissue—atherosclerosis	0.000865	0.0247	CbGeAlD
Dabigatran etexilate—F2—cardiovascular system—atherosclerosis	0.00082	0.0234	CbGeAlD
Dabigatran etexilate—Haemoptysis—Niacin—atherosclerosis	0.000807	0.0118	CcSEcCtD
Dabigatran etexilate—CES2—adipose tissue—atherosclerosis	0.000806	0.023	CbGeAlD
Dabigatran etexilate—Gastrooesophageal reflux disease—Ezetimibe—atherosclerosis	0.000755	0.011	CcSEcCtD
Dabigatran etexilate—Bone disorder—Ezetimibe—atherosclerosis	0.000755	0.011	CcSEcCtD
Dabigatran etexilate—CES1—cardiovascular system—atherosclerosis	0.000753	0.0215	CbGeAlD
Dabigatran etexilate—NQO2—adipose tissue—atherosclerosis	0.00072	0.0206	CbGeAlD
Dabigatran etexilate—Musculoskeletal pain—Lovastatin—atherosclerosis	0.000704	0.0103	CcSEcCtD
Dabigatran etexilate—UGT1A9—liver—atherosclerosis	0.000701	0.02	CbGeAlD
Dabigatran etexilate—CES1—adipose tissue—atherosclerosis	0.000664	0.019	CbGeAlD
Dabigatran etexilate—Bone disorder—Niacin—atherosclerosis	0.000661	0.00965	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Niacin—atherosclerosis	0.000657	0.00959	CcSEcCtD
Dabigatran etexilate—Gout—Niacin—atherosclerosis	0.00064	0.00934	CcSEcCtD
Dabigatran etexilate—Musculoskeletal pain—Pravastatin—atherosclerosis	0.000595	0.00869	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Lovastatin—atherosclerosis	0.000578	0.00843	CcSEcCtD
Dabigatran etexilate—UGT2B7—liver—atherosclerosis	0.000565	0.0162	CbGeAlD
Dabigatran etexilate—CES2—liver—atherosclerosis	0.000565	0.0162	CbGeAlD
Dabigatran etexilate—Oesophagitis—Niacin—atherosclerosis	0.000546	0.00797	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Simvastatin—atherosclerosis	0.00054	0.00789	CcSEcCtD
Dabigatran etexilate—Influenza—Rosuvastatin—atherosclerosis	0.000515	0.00751	CcSEcCtD
Dabigatran etexilate—F2—liver—atherosclerosis	0.000507	0.0145	CbGeAlD
Dabigatran etexilate—NQO2—liver—atherosclerosis	0.000505	0.0144	CbGeAlD
Dabigatran etexilate—Pain in extremity—Lovastatin—atherosclerosis	0.000505	0.00737	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Niacin—atherosclerosis	0.000496	0.00724	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Ezetimibe—atherosclerosis	0.000495	0.00723	CcSEcCtD
Dabigatran etexilate—Bronchitis—Rosuvastatin—atherosclerosis	0.000495	0.00723	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Pravastatin—atherosclerosis	0.000488	0.00713	CcSEcCtD
Dabigatran etexilate—CES1—liver—atherosclerosis	0.000465	0.0133	CbGeAlD
Dabigatran etexilate—Liver function test abnormal—Ezetimibe—atherosclerosis	0.000457	0.00667	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Rosuvastatin—atherosclerosis	0.000446	0.00651	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.000446	0.00651	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Ezetimibe—atherosclerosis	0.000443	0.00646	CcSEcCtD
Dabigatran etexilate—Gastritis—Ezetimibe—atherosclerosis	0.000438	0.0064	CcSEcCtD
Dabigatran etexilate—Haematuria—Rosuvastatin—atherosclerosis	0.000438	0.00639	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.000437	0.00637	CcSEcCtD
Dabigatran etexilate—Influenza—Lovastatin—atherosclerosis	0.000436	0.00637	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.000434	0.00634	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Niacin—atherosclerosis	0.000434	0.00633	CcSEcCtD
Dabigatran etexilate—Sinusitis—Rosuvastatin—atherosclerosis	0.000431	0.00629	CcSEcCtD
Dabigatran etexilate—Influenza—Ezetimibe—atherosclerosis	0.000428	0.00625	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Lovastatin—atherosclerosis	0.000418	0.00611	CcSEcCtD
Dabigatran etexilate—Gastritis—Simvastatin—atherosclerosis	0.000418	0.0061	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Niacin—atherosclerosis	0.0004	0.00584	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.000398	0.00581	CcSEcCtD
Dabigatran etexilate—ABCB1—blood vessel—atherosclerosis	0.000395	0.0113	CbGeAlD
Dabigatran etexilate—Liver function test abnormal—Pravastatin—atherosclerosis	0.000394	0.00575	CcSEcCtD
Dabigatran etexilate—Bronchitis—Simvastatin—atherosclerosis	0.000392	0.00573	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Simvastatin—atherosclerosis	0.000391	0.00571	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Pravastatin—atherosclerosis	0.000382	0.00557	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Ezetimibe—atherosclerosis	0.000382	0.00557	CcSEcCtD
Dabigatran etexilate—Infestation—Ezetimibe—atherosclerosis	0.000382	0.00557	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000379	0.00554	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Lovastatin—atherosclerosis	0.000378	0.00552	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.000377	0.0055	CcSEcCtD
Dabigatran etexilate—Dysphagia—Niacin—atherosclerosis	0.000375	0.00547	CcSEcCtD
Dabigatran etexilate—Influenza—Niacin—atherosclerosis	0.000375	0.00547	CcSEcCtD
Dabigatran etexilate—Influenza—Pravastatin—atherosclerosis	0.000369	0.00539	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Niacin—atherosclerosis	0.000365	0.00533	CcSEcCtD
Dabigatran etexilate—Sinusitis—Lovastatin—atherosclerosis	0.000365	0.00533	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000361	0.00527	CcSEcCtD
Dabigatran etexilate—Bronchitis—Niacin—atherosclerosis	0.00036	0.00526	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Pravastatin—atherosclerosis	0.000359	0.00525	CcSEcCtD
Dabigatran etexilate—Sinusitis—Ezetimibe—atherosclerosis	0.000358	0.00523	CcSEcCtD
Dabigatran etexilate—Flatulence—Rosuvastatin—atherosclerosis	0.000354	0.00516	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000343	0.00501	CcSEcCtD
Dabigatran etexilate—Sinusitis—Simvastatin—atherosclerosis	0.000341	0.00498	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Ezetimibe—atherosclerosis	0.000337	0.00493	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000337	0.00491	CcSEcCtD
Dabigatran etexilate—Angioedema—Rosuvastatin—atherosclerosis	0.000328	0.00478	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000324	0.00473	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Pravastatin—atherosclerosis	0.000322	0.00471	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Pravastatin—atherosclerosis	0.00032	0.00467	CcSEcCtD
Dabigatran etexilate—Cough—Rosuvastatin—atherosclerosis	0.000313	0.00457	CcSEcCtD
Dabigatran etexilate—Angiopathy—Ezetimibe—atherosclerosis	0.000311	0.00454	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Ezetimibe—atherosclerosis	0.000309	0.00452	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000309	0.00451	CcSEcCtD
Dabigatran etexilate—Sinusitis—Pravastatin—atherosclerosis	0.000309	0.00451	CcSEcCtD
Dabigatran etexilate—Arthralgia—Rosuvastatin—atherosclerosis	0.000305	0.00446	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Niacin—atherosclerosis	0.000301	0.0044	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Niacin—atherosclerosis	0.0003	0.00438	CcSEcCtD
Dabigatran etexilate—Flatulence—Lovastatin—atherosclerosis	0.0003	0.00437	CcSEcCtD
Dabigatran etexilate—Malnutrition—Ezetimibe—atherosclerosis	0.000298	0.00435	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Niacin—atherosclerosis	0.000295	0.00431	CcSEcCtD
Dabigatran etexilate—Back pain—Lovastatin—atherosclerosis	0.000294	0.00429	CcSEcCtD
Dabigatran etexilate—Flatulence—Ezetimibe—atherosclerosis	0.000294	0.00429	CcSEcCtD
Dabigatran etexilate—Infection—Rosuvastatin—atherosclerosis	0.000291	0.00425	CcSEcCtD
Dabigatran etexilate—Back pain—Ezetimibe—atherosclerosis	0.000288	0.00421	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000287	0.00419	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000287	0.00418	CcSEcCtD
Dabigatran etexilate—Flatulence—Simvastatin—atherosclerosis	0.00028	0.00409	CcSEcCtD
Dabigatran etexilate—Angioedema—Lovastatin—atherosclerosis	0.000278	0.00405	CcSEcCtD
Dabigatran etexilate—Anaemia—Ezetimibe—atherosclerosis	0.000276	0.00402	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Pravastatin—atherosclerosis	0.000274	0.004	CcSEcCtD
Dabigatran etexilate—Angioedema—Ezetimibe—atherosclerosis	0.000272	0.00398	CcSEcCtD
Dabigatran etexilate—Angiopathy—Niacin—atherosclerosis	0.000272	0.00397	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000267	0.00389	CcSEcCtD
Dabigatran etexilate—Palpitations—Ezetimibe—atherosclerosis	0.000264	0.00385	CcSEcCtD
Dabigatran etexilate—Anaemia—Simvastatin—atherosclerosis	0.000263	0.00384	CcSEcCtD
Dabigatran etexilate—Malnutrition—Niacin—atherosclerosis	0.000261	0.00381	CcSEcCtD
Dabigatran etexilate—Cough—Ezetimibe—atherosclerosis	0.00026	0.0038	CcSEcCtD
Dabigatran etexilate—Angioedema—Simvastatin—atherosclerosis	0.00026	0.00379	CcSEcCtD
Dabigatran etexilate—Chest pain—Lovastatin—atherosclerosis	0.000259	0.00378	CcSEcCtD
Dabigatran etexilate—Arthralgia—Lovastatin—atherosclerosis	0.000259	0.00378	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Rosuvastatin—atherosclerosis	0.000258	0.00376	CcSEcCtD
Dabigatran etexilate—Hypertension—Ezetimibe—atherosclerosis	0.000257	0.00376	CcSEcCtD
Dabigatran etexilate—Flatulence—Niacin—atherosclerosis	0.000257	0.00376	CcSEcCtD
Dabigatran etexilate—Arthralgia—Ezetimibe—atherosclerosis	0.000254	0.00371	CcSEcCtD
Dabigatran etexilate—Chest pain—Ezetimibe—atherosclerosis	0.000254	0.00371	CcSEcCtD
Dabigatran etexilate—Flatulence—Pravastatin—atherosclerosis	0.000253	0.0037	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000252	0.00368	CcSEcCtD
Dabigatran etexilate—Constipation—Rosuvastatin—atherosclerosis	0.00025	0.00365	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Lovastatin—atherosclerosis	0.000248	0.00362	CcSEcCtD
Dabigatran etexilate—Infection—Lovastatin—atherosclerosis	0.000247	0.0036	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000243	0.00355	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Lovastatin—atherosclerosis	0.000243	0.00355	CcSEcCtD
Dabigatran etexilate—Arthralgia—Simvastatin—atherosclerosis	0.000242	0.00353	CcSEcCtD
Dabigatran etexilate—Chest pain—Simvastatin—atherosclerosis	0.000242	0.00353	CcSEcCtD
Dabigatran etexilate—Infection—Ezetimibe—atherosclerosis	0.000242	0.00353	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000239	0.00349	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Ezetimibe—atherosclerosis	0.000239	0.00348	CcSEcCtD
Dabigatran etexilate—Angioedema—Niacin—atherosclerosis	0.000239	0.00348	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000238	0.00348	CcSEcCtD
Dabigatran etexilate—Anaemia—Pravastatin—atherosclerosis	0.000238	0.00347	CcSEcCtD
Dabigatran etexilate—Skin disorder—Ezetimibe—atherosclerosis	0.000236	0.00345	CcSEcCtD
Dabigatran etexilate—Angioedema—Pravastatin—atherosclerosis	0.000235	0.00343	CcSEcCtD
Dabigatran etexilate—Syncope—Niacin—atherosclerosis	0.000234	0.00342	CcSEcCtD
Dabigatran etexilate—Urticaria—Rosuvastatin—atherosclerosis	0.000233	0.00339	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Simvastatin—atherosclerosis	0.000232	0.00339	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Rosuvastatin—atherosclerosis	0.000231	0.00338	CcSEcCtD
Dabigatran etexilate—Palpitations—Niacin—atherosclerosis	0.000231	0.00337	CcSEcCtD
Dabigatran etexilate—Infection—Simvastatin—atherosclerosis	0.000231	0.00337	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Niacin—atherosclerosis	0.000229	0.00335	CcSEcCtD
Dabigatran etexilate—Cough—Niacin—atherosclerosis	0.000228	0.00333	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Simvastatin—atherosclerosis	0.000227	0.00332	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000226	0.0033	CcSEcCtD
Dabigatran etexilate—Cough—Pravastatin—atherosclerosis	0.000224	0.00327	CcSEcCtD
Dabigatran etexilate—Arthralgia—Niacin—atherosclerosis	0.000222	0.00324	CcSEcCtD
Dabigatran etexilate—Hypertension—Pravastatin—atherosclerosis	0.000222	0.00324	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000222	0.00324	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Lovastatin—atherosclerosis	0.000221	0.00323	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000221	0.00322	CcSEcCtD
Dabigatran etexilate—Arthralgia—Pravastatin—atherosclerosis	0.000219	0.00319	CcSEcCtD
Dabigatran etexilate—Chest pain—Pravastatin—atherosclerosis	0.000219	0.00319	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Lovastatin—atherosclerosis	0.000218	0.00319	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Ezetimibe—atherosclerosis	0.000217	0.00317	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000216	0.00315	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Ezetimibe—atherosclerosis	0.000214	0.00313	CcSEcCtD
Dabigatran etexilate—Fatigue—Lovastatin—atherosclerosis	0.000214	0.00312	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Niacin—atherosclerosis	0.000213	0.00311	CcSEcCtD
Dabigatran etexilate—Constipation—Lovastatin—atherosclerosis	0.000212	0.0031	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000211	0.00309	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00021	0.00307	CcSEcCtD
Dabigatran etexilate—Asthenia—Rosuvastatin—atherosclerosis	0.00021	0.00307	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Pravastatin—atherosclerosis	0.00021	0.00306	CcSEcCtD
Dabigatran etexilate—Fatigue—Ezetimibe—atherosclerosis	0.00021	0.00306	CcSEcCtD
Dabigatran etexilate—Shock—Niacin—atherosclerosis	0.00021	0.00306	CcSEcCtD
Dabigatran etexilate—Infection—Pravastatin—atherosclerosis	0.000208	0.00304	CcSEcCtD
Dabigatran etexilate—Constipation—Ezetimibe—atherosclerosis	0.000208	0.00304	CcSEcCtD
Dabigatran etexilate—Pruritus—Rosuvastatin—atherosclerosis	0.000207	0.00302	CcSEcCtD
Dabigatran etexilate—Skin disorder—Niacin—atherosclerosis	0.000207	0.00302	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Simvastatin—atherosclerosis	0.000207	0.00302	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Pravastatin—atherosclerosis	0.000205	0.003	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Simvastatin—atherosclerosis	0.000204	0.00298	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000203	0.00296	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.0002	0.00292	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Rosuvastatin—atherosclerosis	0.0002	0.00292	CcSEcCtD
Dabigatran etexilate—Fatigue—Simvastatin—atherosclerosis	0.0002	0.00292	CcSEcCtD
Dabigatran etexilate—Hypotension—Niacin—atherosclerosis	0.000199	0.00291	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000199	0.0029	CcSEcCtD
Dabigatran etexilate—Constipation—Simvastatin—atherosclerosis	0.000198	0.0029	CcSEcCtD
Dabigatran etexilate—Urticaria—Lovastatin—atherosclerosis	0.000197	0.00288	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Lovastatin—atherosclerosis	0.000196	0.00286	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000194	0.00283	CcSEcCtD
Dabigatran etexilate—Dizziness—Rosuvastatin—atherosclerosis	0.000194	0.00283	CcSEcCtD
Dabigatran etexilate—Urticaria—Ezetimibe—atherosclerosis	0.000193	0.00282	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Ezetimibe—atherosclerosis	0.000192	0.00281	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000191	0.00279	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Niacin—atherosclerosis	0.00019	0.00277	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00019	0.00277	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Niacin—atherosclerosis	0.000188	0.00274	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Pravastatin—atherosclerosis	0.000187	0.00273	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Pravastatin—atherosclerosis	0.000185	0.0027	CcSEcCtD
Dabigatran etexilate—Rash—Rosuvastatin—atherosclerosis	0.000185	0.00269	CcSEcCtD
Dabigatran etexilate—Dermatitis—Rosuvastatin—atherosclerosis	0.000184	0.00269	CcSEcCtD
Dabigatran etexilate—Urticaria—Simvastatin—atherosclerosis	0.000184	0.00269	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Niacin—atherosclerosis	0.000184	0.00269	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Simvastatin—atherosclerosis	0.000183	0.00268	CcSEcCtD
Dabigatran etexilate—Headache—Rosuvastatin—atherosclerosis	0.000183	0.00268	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Lovastatin—atherosclerosis	0.000183	0.00267	CcSEcCtD
Dabigatran etexilate—Fatigue—Pravastatin—atherosclerosis	0.000181	0.00264	CcSEcCtD
Dabigatran etexilate—Constipation—Pravastatin—atherosclerosis	0.000179	0.00262	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Ezetimibe—atherosclerosis	0.000179	0.00262	CcSEcCtD
Dabigatran etexilate—Asthenia—Lovastatin—atherosclerosis	0.000178	0.0026	CcSEcCtD
Dabigatran etexilate—ABCB1—cardiovascular system—atherosclerosis	0.000176	0.00504	CbGeAlD
Dabigatran etexilate—Pruritus—Lovastatin—atherosclerosis	0.000176	0.00256	CcSEcCtD
Dabigatran etexilate—Asthenia—Ezetimibe—atherosclerosis	0.000175	0.00255	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Niacin—atherosclerosis	0.000174	0.00254	CcSEcCtD
Dabigatran etexilate—Nausea—Rosuvastatin—atherosclerosis	0.000174	0.00254	CcSEcCtD
Dabigatran etexilate—Pruritus—Ezetimibe—atherosclerosis	0.000172	0.00251	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000172	0.0025	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Simvastatin—atherosclerosis	0.000171	0.0025	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Lovastatin—atherosclerosis	0.00017	0.00248	CcSEcCtD
Dabigatran etexilate—Urticaria—Niacin—atherosclerosis	0.000169	0.00247	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Niacin—atherosclerosis	0.000168	0.00246	CcSEcCtD
Dabigatran etexilate—Urticaria—Pravastatin—atherosclerosis	0.000167	0.00243	CcSEcCtD
Dabigatran etexilate—Asthenia—Simvastatin—atherosclerosis	0.000167	0.00243	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Ezetimibe—atherosclerosis	0.000167	0.00243	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Pravastatin—atherosclerosis	0.000166	0.00242	CcSEcCtD
Dabigatran etexilate—Pruritus—Simvastatin—atherosclerosis	0.000164	0.0024	CcSEcCtD
Dabigatran etexilate—Dizziness—Lovastatin—atherosclerosis	0.000164	0.00239	CcSEcCtD
Dabigatran etexilate—Dizziness—Ezetimibe—atherosclerosis	0.000161	0.00235	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Simvastatin—atherosclerosis	0.000159	0.00232	CcSEcCtD
Dabigatran etexilate—Vomiting—Lovastatin—atherosclerosis	0.000158	0.0023	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Niacin—atherosclerosis	0.000157	0.00229	CcSEcCtD
Dabigatran etexilate—Rash—Lovastatin—atherosclerosis	0.000156	0.00228	CcSEcCtD
Dabigatran etexilate—Dermatitis—Lovastatin—atherosclerosis	0.000156	0.00228	CcSEcCtD
Dabigatran etexilate—ABCB1—adipose tissue—atherosclerosis	0.000155	0.00444	CbGeAlD
Dabigatran etexilate—Headache—Lovastatin—atherosclerosis	0.000155	0.00227	CcSEcCtD
Dabigatran etexilate—Vomiting—Ezetimibe—atherosclerosis	0.000155	0.00226	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Pravastatin—atherosclerosis	0.000155	0.00226	CcSEcCtD
Dabigatran etexilate—Dizziness—Simvastatin—atherosclerosis	0.000153	0.00224	CcSEcCtD
Dabigatran etexilate—Rash—Ezetimibe—atherosclerosis	0.000153	0.00224	CcSEcCtD
Dabigatran etexilate—Dermatitis—Ezetimibe—atherosclerosis	0.000153	0.00224	CcSEcCtD
Dabigatran etexilate—Asthenia—Niacin—atherosclerosis	0.000153	0.00223	CcSEcCtD
Dabigatran etexilate—Headache—Ezetimibe—atherosclerosis	0.000152	0.00223	CcSEcCtD
Dabigatran etexilate—Pruritus—Niacin—atherosclerosis	0.000151	0.0022	CcSEcCtD
Dabigatran etexilate—Asthenia—Pravastatin—atherosclerosis	0.000151	0.0022	CcSEcCtD
Dabigatran etexilate—Pruritus—Pravastatin—atherosclerosis	0.000148	0.00217	CcSEcCtD
Dabigatran etexilate—Vomiting—Simvastatin—atherosclerosis	0.000148	0.00215	CcSEcCtD
Dabigatran etexilate—Nausea—Lovastatin—atherosclerosis	0.000147	0.00215	CcSEcCtD
Dabigatran etexilate—Rash—Simvastatin—atherosclerosis	0.000146	0.00214	CcSEcCtD
Dabigatran etexilate—Dermatitis—Simvastatin—atherosclerosis	0.000146	0.00213	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Niacin—atherosclerosis	0.000146	0.00213	CcSEcCtD
Dabigatran etexilate—Headache—Simvastatin—atherosclerosis	0.000145	0.00212	CcSEcCtD
Dabigatran etexilate—Nausea—Ezetimibe—atherosclerosis	0.000145	0.00211	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Pravastatin—atherosclerosis	0.000144	0.0021	CcSEcCtD
Dabigatran etexilate—Dizziness—Niacin—atherosclerosis	0.000141	0.00206	CcSEcCtD
Dabigatran etexilate—Dizziness—Pravastatin—atherosclerosis	0.000139	0.00203	CcSEcCtD
Dabigatran etexilate—Nausea—Simvastatin—atherosclerosis	0.000138	0.00201	CcSEcCtD
Dabigatran etexilate—Vomiting—Niacin—atherosclerosis	0.000135	0.00198	CcSEcCtD
Dabigatran etexilate—Rash—Niacin—atherosclerosis	0.000134	0.00196	CcSEcCtD
Dabigatran etexilate—Dermatitis—Niacin—atherosclerosis	0.000134	0.00196	CcSEcCtD
Dabigatran etexilate—Headache—Niacin—atherosclerosis	0.000134	0.00195	CcSEcCtD
Dabigatran etexilate—Vomiting—Pravastatin—atherosclerosis	0.000133	0.00195	CcSEcCtD
Dabigatran etexilate—Rash—Pravastatin—atherosclerosis	0.000132	0.00193	CcSEcCtD
Dabigatran etexilate—Dermatitis—Pravastatin—atherosclerosis	0.000132	0.00193	CcSEcCtD
Dabigatran etexilate—Headache—Pravastatin—atherosclerosis	0.000131	0.00192	CcSEcCtD
Dabigatran etexilate—Nausea—Niacin—atherosclerosis	0.000127	0.00185	CcSEcCtD
Dabigatran etexilate—Nausea—Pravastatin—atherosclerosis	0.000125	0.00182	CcSEcCtD
Dabigatran etexilate—ABCB1—liver—atherosclerosis	0.000109	0.00312	CbGeAlD
Dabigatran etexilate—UGT2B15—Metabolism—AGT—atherosclerosis	1.41e-05	0.000137	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KNG1—atherosclerosis	1.39e-05	0.000135	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP27A1—atherosclerosis	1.39e-05	0.000135	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—UTS2—atherosclerosis	1.39e-05	0.000135	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AGTR1—atherosclerosis	1.38e-05	0.000135	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—APOE—atherosclerosis	1.38e-05	0.000134	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALOX5—atherosclerosis	1.38e-05	0.000134	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—atherosclerosis	1.38e-05	0.000134	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IGF1—atherosclerosis	1.37e-05	0.000134	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	1.37e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CAV1—atherosclerosis	1.37e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—APOA1—atherosclerosis	1.37e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MMP1—atherosclerosis	1.35e-05	0.000131	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	1.34e-05	0.00013	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—AGT—atherosclerosis	1.34e-05	0.00013	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CX3CR1—atherosclerosis	1.33e-05	0.000129	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASR—atherosclerosis	1.33e-05	0.000129	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—TRPV1—atherosclerosis	1.33e-05	0.000129	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALOX15—atherosclerosis	1.32e-05	0.000128	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALOX5AP—atherosclerosis	1.32e-05	0.000128	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APOA2—atherosclerosis	1.32e-05	0.000128	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PLA2G2A—atherosclerosis	1.32e-05	0.000128	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—LEP—atherosclerosis	1.31e-05	0.000127	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SERPINE1—atherosclerosis	1.31e-05	0.000127	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CX3CL1—atherosclerosis	1.3e-05	0.000127	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ALB—atherosclerosis	1.3e-05	0.000127	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCG5—atherosclerosis	1.3e-05	0.000127	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	1.3e-05	0.000126	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—EDN1—atherosclerosis	1.29e-05	0.000126	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CCL5—atherosclerosis	1.28e-05	0.000125	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ABCG5—atherosclerosis	1.28e-05	0.000124	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TGFB1—atherosclerosis	1.27e-05	0.000123	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—LPA—atherosclerosis	1.26e-05	0.000122	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CG—atherosclerosis	1.25e-05	0.000121	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NOS3—atherosclerosis	1.25e-05	0.000121	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NAMPT—atherosclerosis	1.24e-05	0.00012	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CNR2—atherosclerosis	1.24e-05	0.00012	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL8—atherosclerosis	1.24e-05	0.00012	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MMP3—atherosclerosis	1.23e-05	0.00012	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	1.23e-05	0.00012	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—LIPC—atherosclerosis	1.23e-05	0.000119	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—APOC3—atherosclerosis	1.22e-05	0.000119	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PRKCG—atherosclerosis	1.22e-05	0.000118	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—BGN—atherosclerosis	1.22e-05	0.000118	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—LDLR—atherosclerosis	1.21e-05	0.000118	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.21e-05	0.000117	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APOA5—atherosclerosis	1.21e-05	0.000117	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—atherosclerosis	1.2e-05	0.000117	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPARG—atherosclerosis	1.2e-05	0.000117	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CETP—atherosclerosis	1.19e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TNF—atherosclerosis	1.18e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LDLRAP1—atherosclerosis	1.18e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—INS—atherosclerosis	1.18e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EDN1—atherosclerosis	1.17e-05	0.000114	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.17e-05	0.000114	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL5—atherosclerosis	1.16e-05	0.000113	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PLA2G1B—atherosclerosis	1.16e-05	0.000113	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.15e-05	0.000111	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.14e-05	0.00011	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SCARB1—atherosclerosis	1.14e-05	0.00011	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.13e-05	0.00011	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALOX5—atherosclerosis	1.12e-05	0.000109	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—INS—atherosclerosis	1.12e-05	0.000109	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	1.11e-05	0.000108	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLTP—atherosclerosis	1.11e-05	0.000108	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PRKCG—atherosclerosis	1.11e-05	0.000108	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VWF—atherosclerosis	1.1e-05	0.000107	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CCL2—atherosclerosis	1.1e-05	0.000107	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APOC3—atherosclerosis	1.1e-05	0.000106	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LDLR—atherosclerosis	1.09e-05	0.000106	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ALB—atherosclerosis	1.08e-05	0.000105	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—IGF1—atherosclerosis	1.08e-05	0.000105	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AGT—atherosclerosis	1.07e-05	0.000104	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—HMGCR—atherosclerosis	1.07e-05	0.000104	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL3—atherosclerosis	1.06e-05	0.000103	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MMP2—atherosclerosis	1.05e-05	0.000102	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—atherosclerosis	1.04e-05	0.000101	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.04e-05	0.000101	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—NOS3—atherosclerosis	1.03e-05	0.000101	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NCF1—atherosclerosis	1.02e-05	9.9e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—AKT1—atherosclerosis	1.02e-05	9.87e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NAMPT—atherosclerosis	1.01e-05	9.77e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1e-05	9.71e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—LIPC—atherosclerosis	9.99e-06	9.71e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APOC3—atherosclerosis	9.93e-06	9.65e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—LDLR—atherosclerosis	9.87e-06	9.59e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AGT—atherosclerosis	9.74e-06	9.46e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CETP—atherosclerosis	9.64e-06	9.37e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LTA4H—atherosclerosis	9.63e-06	9.36e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ABCG8—atherosclerosis	9.63e-06	9.36e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EDNRA—atherosclerosis	9.62e-06	9.34e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCR2—atherosclerosis	9.62e-06	9.34e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CYBA—atherosclerosis	9.58e-06	9.3e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ABCA1—atherosclerosis	9.56e-06	9.29e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CG—atherosclerosis	9.49e-06	9.22e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—atherosclerosis	9.46e-06	9.19e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—CETP—atherosclerosis	9.44e-06	9.17e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PARP1—atherosclerosis	9.38e-06	9.11e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GHRL—atherosclerosis	9.38e-06	9.11e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PLAT—atherosclerosis	9.38e-06	9.11e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SCARB1—atherosclerosis	9.23e-06	8.97e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	8.99e-06	8.73e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—atherosclerosis	8.98e-06	8.72e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HMGCR—atherosclerosis	8.72e-06	8.47e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CXCL8—atherosclerosis	8.7e-06	8.45e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—atherosclerosis	8.64e-06	8.39e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CG—atherosclerosis	8.62e-06	8.37e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MAPK3—atherosclerosis	8.49e-06	8.25e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—PLAT—atherosclerosis	8.32e-06	8.08e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TGFB1—atherosclerosis	8.24e-06	8.01e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KNG1—atherosclerosis	8.23e-06	7.99e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—HMOX1—atherosclerosis	8.21e-06	7.97e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AGTR1—atherosclerosis	8.18e-06	7.95e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL2—atherosclerosis	8.02e-06	7.79e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PLG—atherosclerosis	7.97e-06	7.74e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	7.86e-06	7.64e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—APOB—atherosclerosis	7.86e-06	7.63e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCA1—atherosclerosis	7.77e-06	7.55e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTM1—atherosclerosis	7.65e-06	7.43e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ABCG1—atherosclerosis	7.61e-06	7.4e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SOCS3—atherosclerosis	7.55e-06	7.33e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—LPL—atherosclerosis	7.5e-06	7.29e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—atherosclerosis	7.5e-06	7.28e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	7.37e-06	7.16e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GPX1—atherosclerosis	7.32e-06	7.11e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP3—atherosclerosis	7.29e-06	7.08e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF2—atherosclerosis	7.26e-06	7.05e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—FABP4—atherosclerosis	7.16e-06	6.95e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LCAT—atherosclerosis	7.16e-06	6.95e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CD36—atherosclerosis	7.13e-06	6.93e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—PLG—atherosclerosis	7.08e-06	6.87e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APOB—atherosclerosis	7.05e-06	6.84e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOA4—atherosclerosis	7.03e-06	6.83e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL8—atherosclerosis	6.99e-06	6.79e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EDN1—atherosclerosis	6.93e-06	6.74e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP7A1—atherosclerosis	6.9e-06	6.71e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL5—atherosclerosis	6.88e-06	6.68e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	6.81e-06	6.61e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MTHFR—atherosclerosis	6.76e-06	6.56e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LPL—atherosclerosis	6.73e-06	6.54e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HMOX1—atherosclerosis	6.67e-06	6.48e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARA—atherosclerosis	6.63e-06	6.44e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PRKCG—atherosclerosis	6.54e-06	6.35e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	6.53e-06	6.34e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	6.44e-06	6.25e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AGT—atherosclerosis	6.42e-06	6.24e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APOB—atherosclerosis	6.39e-06	6.2e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP27A1—atherosclerosis	6.38e-06	6.2e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SPP1—atherosclerosis	6.37e-06	6.19e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL8—atherosclerosis	6.34e-06	6.16e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—APOE—atherosclerosis	6.29e-06	6.11e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	6.26e-06	6.08e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	6.25e-06	6.07e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CAV1—atherosclerosis	6.23e-06	6.05e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—APOA1—atherosclerosis	6.22e-06	6.04e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTM1—atherosclerosis	6.21e-06	6.03e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—LPL—atherosclerosis	6.1e-06	5.92e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOA2—atherosclerosis	6.05e-06	5.88e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALOX5AP—atherosclerosis	6.05e-06	5.88e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLA2G2A—atherosclerosis	6.05e-06	5.88e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALOX15—atherosclerosis	6.05e-06	5.88e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ABCG5—atherosclerosis	5.97e-06	5.8e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GPX1—atherosclerosis	5.95e-06	5.78e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFB—atherosclerosis	5.9e-06	5.73e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	5.83e-06	5.67e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CD36—atherosclerosis	5.79e-06	5.63e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LPA—atherosclerosis	5.77e-06	5.61e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AGT—atherosclerosis	5.76e-06	5.59e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—atherosclerosis	5.73e-06	5.56e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CG—atherosclerosis	5.68e-06	5.51e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LEP—atherosclerosis	5.64e-06	5.48e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APOE—atherosclerosis	5.64e-06	5.48e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—BGN—atherosclerosis	5.59e-06	5.43e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CAV1—atherosclerosis	5.59e-06	5.43e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APOA1—atherosclerosis	5.58e-06	5.42e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOA5—atherosclerosis	5.53e-06	5.37e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MTHFR—atherosclerosis	5.49e-06	5.33e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARG—atherosclerosis	5.48e-06	5.32e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARA—atherosclerosis	5.39e-06	5.23e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ESR1—atherosclerosis	5.38e-06	5.23e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—INS—atherosclerosis	5.37e-06	5.22e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLA2G1B—atherosclerosis	5.33e-06	5.17e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	5.28e-06	5.12e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AGT—atherosclerosis	5.22e-06	5.07e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALOX5—atherosclerosis	5.14e-06	5e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APOE—atherosclerosis	5.11e-06	4.97e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CG—atherosclerosis	5.09e-06	4.94e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CAV1—atherosclerosis	5.06e-06	4.92e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APOA1—atherosclerosis	5.05e-06	4.91e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	4.95e-06	4.81e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALB—atherosclerosis	4.93e-06	4.79e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAPK3—atherosclerosis	4.87e-06	4.73e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—INS—atherosclerosis	4.82e-06	4.68e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—atherosclerosis	4.76e-06	4.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL2—atherosclerosis	4.74e-06	4.6e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NOS3—atherosclerosis	4.71e-06	4.58e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1—atherosclerosis	4.66e-06	4.53e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NAMPT—atherosclerosis	4.61e-06	4.48e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CG—atherosclerosis	4.61e-06	4.48e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LIPC—atherosclerosis	4.58e-06	4.45e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOC3—atherosclerosis	4.56e-06	4.43e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LDLR—atherosclerosis	4.53e-06	4.4e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARG—atherosclerosis	4.45e-06	4.32e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SERPINE1—atherosclerosis	4.43e-06	4.3e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CETP—atherosclerosis	4.42e-06	4.3e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—INS—atherosclerosis	4.37e-06	4.24e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	4.34e-06	4.22e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—atherosclerosis	4.31e-06	4.19e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SCARB1—atherosclerosis	4.24e-06	4.11e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOS3—atherosclerosis	4.23e-06	4.1e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALB—atherosclerosis	4e-06	3.89e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HMGCR—atherosclerosis	4e-06	3.89e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	3.92e-06	3.81e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NOS3—atherosclerosis	3.83e-06	3.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL8—atherosclerosis	3.75e-06	3.64e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—atherosclerosis	3.62e-06	3.52e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ABCA1—atherosclerosis	3.57e-06	3.46e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—atherosclerosis	3.56e-06	3.46e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—atherosclerosis	3.5e-06	3.4e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—atherosclerosis	3.39e-06	3.29e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NFKB1—atherosclerosis	3.35e-06	3.26e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK8—atherosclerosis	3.3e-06	3.2e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—atherosclerosis	3.29e-06	3.19e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HMOX1—atherosclerosis	3.06e-06	2.97e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—atherosclerosis	3.04e-06	2.96e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—atherosclerosis	3.01e-06	2.93e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOB—atherosclerosis	2.93e-06	2.85e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK3—atherosclerosis	2.88e-06	2.8e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTM1—atherosclerosis	2.85e-06	2.77e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LPL—atherosclerosis	2.8e-06	2.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—atherosclerosis	2.79e-06	2.71e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPX1—atherosclerosis	2.73e-06	2.65e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CD36—atherosclerosis	2.66e-06	2.58e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTHFR—atherosclerosis	2.52e-06	2.45e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARA—atherosclerosis	2.47e-06	2.4e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AGT—atherosclerosis	2.39e-06	2.32e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOE—atherosclerosis	2.34e-06	2.28e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CAV1—atherosclerosis	2.32e-06	2.26e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOA1—atherosclerosis	2.32e-06	2.25e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—atherosclerosis	2.17e-06	2.1e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CG—atherosclerosis	2.12e-06	2.06e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—atherosclerosis	2.11e-06	2.05e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARG—atherosclerosis	2.04e-06	1.98e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—INS—atherosclerosis	2e-06	1.95e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—atherosclerosis	1.94e-06	1.89e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALB—atherosclerosis	1.84e-06	1.78e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—atherosclerosis	1.76e-06	1.71e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NOS3—atherosclerosis	1.76e-06	1.71e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—atherosclerosis	1.61e-06	1.56e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—atherosclerosis	8.08e-07	7.84e-06	CbGpPWpGaD
